RIGHTS ISSUE WITH WARRANTS APPROVED! TIME TO FLY SOON?!
Seasoned investors that are familiar with corporate exercise would definitely be no stranger to rights issue. But for new investors, rights issue is commonly a way for listed companies to raise additional capital from shareholders – sometimes it also comes with a sweetener, warrant.
How impactful is warrant on the share price? Just take a look at these few companies share price after bonus issue or rights issue that comes with warrant.
Of course, there are plenty more examples where companies that issued free warrants might spike up. But why is that so?
Warrant – as a financial derivative which carries the ability to allow its holder to have the right but not obligated to convert it into mother share, often seen as an opportunity to arbitrage. It is an advanced technique that often used by seasoned investors but to put it in plain English, some big holders of warrant might “push” the mother share price to increase the attractiveness in warrant due to the conversion gap and the arbitrage opportunity.
However, Kanger International Berhad (KLSE: KANGER) – the recent darling of vaccine theme play had finally gotten their approval from Bursa for the rights issue that comes along with the warrant sweetener.
How do we know for sure KANGER might fly anytime soon? To answer this question, we must study the price movement pattern of the company
As you can see, the company had a downturn in share price and momentum since the vaccine market was slammed hard by the government. But what we could tell from the chart is that there is an attempt to breakout on 28th May 2021. What could possibly trigger the buying momentum
After going around several forums and platforms, I noticed that there are already rumours being spread on KANGER’s rights issue shall be approved at anytime soon. Perhaps this spiked the buying interest – but unfortunately, the company only announced the good news on yesterday, hence investors might have got in too early.
Nevertheless, with the approval for warrants, I’m sure that KANGER will continue to fly once operator had finished the accumulation of shares – which they already did since 2019 to 2020 and washed most new investors off KANGER by now.
From technical analysis + corporate news standpoint, we could begin our execution on the trade. The for-sure support level for the company is at 6.0 cents level. And the most recent resistance of the company would be at 11.5 cents and 15.0 cents, respectively. This represents a potential downside risk of 20.0%, and for the upside, that would be between 53.3% and 100.0%, representing a risk-to-reward ratio of 2.6 times to 5.0 times!
On the back of years of my trading experience, KANGER will definitely ride on the positive news and depart soon. Do not miss out the ride on this company!
Kanger International Bhd, an investment holding company, engages in the research, development, manufacture, and trade of bamboo flooring and related products in the People's Republic of China. It operates the business across North America, Europe, and Asia. By second halve of the year 2020, Kanger started to explore a plan for a new venture in business: to distribute the Covid-19 vaccines manufactured by Sinopharm in Malaysia. Kanger has tried hard to secure this Covid-19 vaccines business as this new business expected to bring a better results for the company.
THE CURRENT DEVELOPMENT OF KANGER'S BAMBOO BUSINESS
Kanger (017) is a "green" building materials provider, specialising in the manufacturing and trading of bamboo flooring and related products for the residential and commercial markets under its brands 'Kanger' and 'KAR Masterpiece' as well as OEM at the request of its customers. In additional, it also sell strand woven bamboo planks, a semi-finished product from its strand woven bamboo flooring manufacturing process, to furniture and building materials manufacturers as raw materials for their production. The bamboo flooring and related products business is still running well as can be seen at these websites:
On September 2020, Kanger planned to strengthen their bamboo products business. Kanger is on target to become the world’s largest producer of bamboo products with the commencement of a new high-tech bamboo processing plant and R&D centre, which was developed in collaboration with the local government of Jingzhou, Hunan Province, China. Kanger has accumulated vast experience and strong know-how of the bamboo industry, having been involved in the bamboo processing business over the past 16 years.
EFFORTS BY THE COMPANY TO SECURE COVID-19 VACCINE BUSINESS
There are some efforts taken by Kanger to make sure they will successfully enter the Covid-19 distribution business. The chronological list (by date) of the efforts taken are listed below:
1. The Covid-10 vaccine started, when Kanger had entered into a proxy agreement with Shenzhen Public Health Technology Co, Ltd (SZPHT) to procure dealership status from China National Biotec Group Company Ltd (CNBG), which is a subsidiary of China National Pharmaceutical Group Corp (Sinopharm) and distributing it in Southeast Asia.
(Remarks: This agreement has been lapsed because it is only valid until October 8, 2020)
2. Kanger had entered a collaboration agreement with China-based Sinopharm Group Hunan Changde Medical Co Ltd (Sinopharm Group) for the distribution of Covid-19 vaccines developed by China National Biotech Group Company (CNBG) in Malaysia.
4. Kanger International Bhd has received the nod from the National Institutes of Biotechnology Malaysia (NIBM) to distribute Covid-19 vaccines and medical equipment in Malaysia.
5. Kanger International Bhd will receive 10,000 doses of a Covid-19 vaccine developed by state-owned China National Pharmaceutical Group Corp (Sinopharm) for trial purposes.
(Remarks: The first batch of vaccines is expected to arrive in Malaysia on May 2021).
8. MOU with Sabah State Government to obtain Sinopharm Covid-19 vaccines
(Remarks: Will the MOU with Sabah State Government helps the company to obtain approval for Sinopharm Covid-19 vaccine from the government through the National Pharmaceutical Regulatory Agency Negara (NPRA)? )
Report 1: The Sinopharm Covid-19 vaccine is in the process of being approved in Malaysia, including by the National Pharmaceutical Regulatory Agency (NPRA).
“We will ensure that we obtain the required approvals from relevant authorities before we commence distribution of the Sinopharm vaccines.
“Once approvals are obtained, the people of Sabah will be one of the early recipients of the Sinopharm vaccines,” Kuah said.
Report 2: S Kanger International executive director Steven Kuah told reporters that, “the process of registering the Sinopharm vaccine (with NPRA) has started and we hope to receive some good news on its approval soon.”
Report 4: Supplies through Putrajaya is just one of the options available, and that state governments could source their own as long as they are approved by the National Pharmaceutical Regulatory Agency (NPRA) – says Khairy
Therefore, we are hoping that, sooner Kanger will be successful in securing their objective to be an approved Covid-19 vaccines distributor in Malaysia.
* DISCLAIMER: All the information given is not for buy call or sell call purposes.
Perrrgh panjang jual cerita. Panjang2 tak ada guna geng, dari tahun lepas plot cerita yg sama, nk senang, bg link yg kata sinopharm dah diluluskan olin NPRA, simple as that. Other than than taik kucing laaa
It won't instant effect to the counter. By trend and news, government is started to involve more to vaccine. Trusted that sooner or later. Is a good sign for company
Perghhh, ramai nya saleman and promoter, cerita goreng ni dari tahun lepas geng, sekarang nama KJ pun ko promote her, betul2 lihai la lu punya marketing
Personally i feel the price already reach bottom. How much can it go down further? Unless it become pn7. Already hold for so long . No amount of negative comments will drive me to sell. Only feel those holding the shares keep on talking negative must be targeting lower price to buy. No investor holding shares want the price to go down and lost money. In the first place if scam company why want to buy ?????
Khairy macam memberi tahu syarat bahawa lulus WHO penting. Dan NPRA mungkin lebih senang lulus jika vaksin tersebut lulus WHO. KAWAN-KAWAN ADA PANDANGAN LAIN? Untuk dibincang secara rasional. Bukan sekadar idea HATER atau NAYSAYER,
Report 6: The states are free to negotiate with drug makers Moderna and Sinopharm, whose vaccines have been approved by the World Health Organization . Khairy said that as long as the vaccines have been given the green light by the National Pharmaceutical Regulatory Agency, the states are free to procure them.
MZM sy pun berpadangan mcm tu...selepas ditekan oleh ramai pihak supaya segerakan vaksin, mudahkan perolehan vaksin dan sebagainya, dia terpaksa akur...tambahan pula tahap vaksin slow dan sprt x terurus secara tersusun dan lancar....jadi dia bagi tau kelulusan NPRA itu mcm syarat yg mudah...sprt ada kelebihan pada Sinopharm dan kanger(kalau kanger benar dan betul2 terlibat dgn vaksin Sinopharm).
@satriahijau. (kalau kanger benar dan betul2 terlibat dgn vaksin Sinopharm). --------------------- Saya hanya cuba bergantung kepada ini untuk percaya:
Report 1: The Sinopharm Covid-19 vaccine is in the process of being approved in Malaysia, including by the National Pharmaceutical Regulatory Agency (NPRA).
“We will ensure that we obtain the required approvals from relevant authorities before we commence distribution of the Sinopharm vaccines.
“Once approvals are obtained, the people of Sabah will be one of the early recipients of the Sinopharm vaccines,” Kuah said.
Report 2: Kanger International executive director Steven Kuah told reporters that, “the process of registering the Sinopharm vaccine (with NPRA) has started and we hope to receive some good news on its approval soon.”
Thanks to all the sifu comments. I think this counter has a very big gap between buying and selling. Once the gap closes should be stabilized. No rush to invest now. I have some collections since 30/03/21.
Sy bukan x percaya langsung atau terlalu yakin....bimbang MOU yg dibuat x seperti diharapkan...melainkan disusuli dgn kontark dan perjanjian yang serius kedua-dua pihak...MOU ini bila2 boleh di abaikan...sy ambil sikap 50-50 walupun berharap ianya benar2 berlaku....apa pun bila dh naik meroket barulah dipercayai....selagi x naik2 kekalah ia sembang kosong dan lebih kpd Kanger InterScamNational. Pengurusan syrkat kna ambil serius...
@satriahijau. Itu pandangan yang rasional dari awak. Awak lebih kenal Kanger dari saya yang lebih kurang dua minggu baharu mengenali Kanger melalui rujukan google semata-mata.
Saya sendiri pun bukan 100% percaya. Tapi dari segi MOU fasal vaksin ni sahaja (YA),
IANYA SAYA PERCAYA 100% BERJAYA ATAU TIDAK MOU AKAN BERGANTUNG KEPADA BERJAYA ATAU TIDAK KANGER MENDAPATKAN KELULUSAN KERAJAAN DAN NPRA UNTUK MENGEDARKAN VAKSIN SINOPHARM DI MALAYSIA.
GAGAL DAPAT KELULUSAN, GAGAL LAH SEMUA MOU BERKAITAN VAKSIN. LAGI SEKALI LAH JADI MOU TIPU.
me personally waiting for sinopharm, so yes, still lot of vaccines q to approve for NPRA... but remember, kanger is the only one already sign MOU with Zuellig that distribute of vaccine... so once approve, already can run... no need to look for distributor..
maybe some had good follow with yong tai, bintai, solution.. know they progress... but for me i see nothing from other company ready to distribute, only say will bring in and wait for approval.. or i miss out...
IANYA SAYA PERCAYA 100% BERJAYA ATAU TIDAK MOU AKAN BERGANTUNG KEPADA BERJAYA ATAU TIDAK KANGER MENDAPATKAN KELULUSAN KERAJAAN DAN NPRA UNTUK MENGEDARKAN VAKSIN SINOPHARM DI MALAYSIA.
Ya, sy setuju dan memang key pointnya kelulusan dri NPRA-Kerajaan dlm Kanger ada Dato Nur Jazlan(tibalan pengerusi umno johor) ...sejauh mana kemapuan beliau berperanan pemudah cara?
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
gkent2000
268 posts
Posted by gkent2000 > 2021-06-03 13:56 | Report Abuse
https://klse.i3investor.com/blogs/unspokerules/2021-06-03-story-h1566017345-RIGHTS_ISSUE_WITH_WARRANTS_APPROVED_TIME_TO_FLY_SOON.jsp